FDA Approves New Takeda Drug Delivery Option
Company Announcements

FDA Approves New Takeda Drug Delivery Option

Takeda Pharmaceutical Company (TAK) has released an update.

The U.S. FDA has approved Takeda’s ENTYVIO (vedolizumab) for subcutaneous administration as a maintenance therapy for adults with moderately to severely active Crohn’s Disease, expanding its availability alongside the existing IV option. The approval is backed by the VISIBLE 2 clinical trial, which showed that nearly half of the patients achieved long-term clinical remission. This new form of administration offers patients the flexibility to self-administer their treatment at home or on the move.

For further insights into TAK stock, check out TipRanks’ Stock Analysis page.

Looking for more investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Optimize your mobile reading experience. Download the TipRanks App today!